1 January 2017 in Journal of Gynecologic Oncology
MKMujdegul Zayifoglu Karaca
Mujdegul Zayifoglu Karaca
+2
Gultekin M, et al. J Gynecol Oncol. 2017 Jul;28(6):e85. https://doi.org/10.3802/jgo.2017.28.e85
31 January 2022 in Ginekologia Polska
Objectives: Human papillomavirus (HPV) positive patients with and without endocervical polyps is compared with respect to HPV genotypes and presence of pre-invasive diseases. To our knowledge, this is the first and largest report in the literature examining the endocervical polyps in HPV positive cases. Material and methods: Clinicopathological data for the first one million screening patients (n = 1 060 992) from around the entire country during 2015 and 2016 were targeted for this research. Colposcopy, colposcopic surgical diagnostic procedures and final pathology results of 3499 patients with high-risk (HR) HPV-positive were obtained from reference colposcopy centers. Patients with endocervical polyps (n = 243 [6.9 %]) were accepted as experimental arm while patients without any endocervical polyp (n = 3256 [93.1%]) were regarded as the control group. Age, HPV genotype, Pap smear abnormality, and final pathological results were compared between two groups using Student’s t-test and cross-tabulation chi-square test. Results: The incidence of endocervical polyp was found to be 6.9 % in HR HPV-positive women. The most common HPV genotypes observed in both groups were HPV 16 or 18. Abnormal cytology reports (≥ ASC-US) were not significantly different between both groups. However, with respect to final pathological diagnosis, patients with endocervical polyp had significantly lower numbers of pre-invasive diseases (31.3% vs 44.2%; p < 0.10). Conclusions: Endocervical polyps may be more common in patients with HR HPV infections. HPV 18 is observed significantly more, in the HR HPV positive endocervical polyp group. Patients with endocervical polyps do not have increased risk for preinvasive cervical diseases. Objectives: Human papillomavirus (HPV) positive patients with and without endocervical polyps is compared with respect to HPV genotypes and presence of pre-invasive diseases. To our knowledge, this is the first and largest report in the literature examining the endocervical polyps in HPV positive cases. Material and methods: Clinicopathological data for the first one million screening patients (n = 1 060 992) from around the entire country during 2015 and 2016 were targeted for this research. Colposcopy, colposcopic surgical diagnostic procedures and final pathology results of 3499 patients with high-risk (HR) HPV-positive were obtained from reference colposcopy centers. Patients with endocervical polyps (n = 243 [6.9 %]) were accepted as experimental arm while patients without any endocervical polyp (n = 3256 [93.1%]) were regarded as the control group. Age, HPV genotype, Pap smear abnormality, and final pathological results were compared between two groups using Student’s t-test and cross-tabulation chi-square test. Results: The incidence of endocervical polyp was found to be 6.9 % in HR HPV-positive women. The most common HPV genotypes observed in both groups were HPV 16 or 18. Abnormal cytology reports (≥ ASC-US) were not significantly different between both groups. However, with respect to final pathological diagnosis, patients with endocervical polyp had significantly lower numbers of pre-invasive diseases (31.3% vs 44.2%; p < 0.10). Conclusions: Endocervical polyps may be more common in patients with HR HPV infections. HPV 18 is observed significantly more, in the HR HPV positive endocervical polyp group. Patients with endocervical polyps do not have increased risk for preinvasive cervical diseases.
31 December 2020 in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
İnsan papilloma virüsü (HPV), seksüel geçişli hastalıkların en sık sebebi olarak gösterilen enfeksiyöz ajanlardır. 200 ün üzerinde tipi olarak başta anogenital bölge olmak üzere , orofarinks ve solunum sistemleri üzerinde benign lezyonlardan , preinvaziv ve invaziv lezyonlara kadar uzanan geniş bir hastalık yelpazesine sahiptir. Kondiloma akuminatanın gün geçtikçe artan insidansı HPV enfeksiyonları içerinde önemli bir paya sahip olmasını sağlamıştır. Kondiloma akuminata HPV nin görünen lezyonları olarak kabul edilir. Kondiloma akuminata lezyonlarına yönelik, kişilerin kendi kendilerine uygulayabilecekleri ev tedavileri, anestezi altında uygulanan cerrahi tedaviler gibi birden çok tedavi yöntemi vardır. Tedavi seçiminde dikkat edilmesi gereken noktalar, bu enfeksiyonun persistansı ve tekrarlamasını engellemek için önemlidir. Biz bu makale ile kondilomata aküminata lezyonlarına yaklaşımda bilinmesi gerekenler ve uygulanan tedavi yöntemlerini paylaşmak istedik.
3 September 2020 in Archives of Gynecology and Obstetrics
24 June 2023 in Cumhuriyet Medical Journal
Objective: We aimed to evaluate the prognostic role of preoperative serum cancer antigen 125 (CA-125) in endometrioid endometrial cancer for determining the cut-off values for clinicopathological factors. Study design: 161 patients were included in the study. The inclusion criteria were histopathological confirmation of endometrioid endometrial cancer and patients with CA-125 levels measured at most ten days before surgery. The association between CA-125 value and clinicopathological variables were analyzed. Receiver operating characteristic curve statistical tests with clinicopathological factors were used to determine the cut-off values and the prognostic role of CA-125. Results: The median value of CA-125 level was 15.4 (3, 2-577) IU/L. These CA-125 cut-off values ranged from 14.30 to 18.67 IU/L (sensitivity 53%– 100%, specificity 30%–59%). The statistical analysis showed a significant relation between CA-125 value and stage and pelvic-paraaortic lymph nodes metastasis. The average life expectancy of patients with CA-125 ≥15.4 was 102.8±5.9 months, whereas that of patients with CA-125 <15.4 was 120.1±3.4 months. Conclusion: Serum CA-125 levels with endometrioid endometrial cancer are related to the stage of the disease. Lower cut-off values compared to the traditional 35 IU/ml value used in ovarian cancer can be a prognostic factor in patients with endometrioid endometrial cancer.
30 March 2023 in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
Amaç: Bu çalışmada amaç epilepsi tanısı almış ve antiepileptik ilaç kullanan gebelerde epilepsi hastalığının ve uygulanan antiepileptik tedavi protokolünün, anne, fetüs ve yenidoğan üzerine etkisinin değerlendirilmesidir. Gereç ve Yöntemler: Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Kliniği’nde 2015- 2020 tarihleri arasında gebelik takipleri yapılan ve epilepsi tanısı alan 55 gebe çalışmaya dahil edildi. Gebelerin yaşı, gebelik sayısı, doğum sayısı, epilepsi tanı yaşı, beden kitle indeksi (BKİ) , gebelikte sigara kullanımı, gebelik öncesi nöroloji kontrolüne gidip gitmedikleri, gebelik boyunca görülen nöbetlerin türü, hangi trimesterde nöbet geçirildiği ve sıklığı, gebelik sürecinde kullandıkları AEİ’lar ve tedavi protokolleri, gebelikte folik asit kullanımı değerlendirildi. Çalışmaya alınan gebelerde takipleri sırasında ortaya çıkan obstetrik komplikasyonlar ve doğum haftaları kaydedildi. Yenidoğan 1.-5. dk. Apgar skorları, fetal malformasyonlar ve fetal distres gibi erken neonatal sorunlar değerlendirildi. Bulgular: Yaşların ortanca değeri 26 (17-42) olarak bulunmuştur. Gebelik sayısının ortancası 2 (1-8)’dir. Doğum sayısının ortancası 1 (0-6)’dır. Çalışmaya alınan kadınların epilepsi tanı yaşlarının ortalaması ise 15 (3-29)’tir. Hastaların 34 (%61,9)’ü generalize, 2 (%3,6)’si parsiyel nöbet geçirmiştir. 19 (%34,5)’u ise gebelik sürecinde nöbet geçirmemiştir. Gebelik takibi boyunca komplikasyon gelişenlerin ortalaması % 43,6, gelişmeyenlerin ortalaması % 56,4 bulunmuştur. Hamilelikte trimesterlerde geçirilen nöbet sayısı ile 1. dakika Apgar skoru arasında istatistiksel farklılık vardır (p